Biotechnology

A new oral Alzheimer's drug shows potential for a lower, more patient-friendly dose, aiming to replace complex infusions with a simple daily pill.

The pharma giant is acquiring a promising 'best-in-class' PI3Kα inhibitor, SNV4818, in a move to bolster its oncology pipeline and redefine cancer care.

Biotech firm Ribo Life Science reveals a new platform targeting the kidney, heart, and fat tissue, signaling a major shift for RNA-based medicines.

An influential guidelines update expands options for a tough-to-treat bladder cancer, giving patients access to a novel gene therapy beyond its FDA label.

A new campaign inspired by Rosie the Riveter calls on mothers to donate milk, a critical intervention that saves the lives of California's premature infants.

Curia announces major upgrades to its UK sterile manufacturing and US biologics platforms, a strategic move to accelerate drug development timelines.

The National Bleeding Disorders Foundation taps celebrity power for a live event, aiming to spotlight underdiagnosed conditions and transform advocacy.

A new oral drug is being tested with existing therapies, offering a two-pronged attack on the glycogen buildup that defines this debilitating rare disease.

Biotech firm Humacyte raises $20M to accelerate sales of its FDA-approved Symvess® and fund crucial trials for new hemodialysis applications.

With pivotal trials advancing, key FDA alignment, and a strong cash position, Taysha Gene Therapies charts a clear path toward a potential breakthrough.

With the FDA mandating a move from animal testing, BioIVT is positioning itself at the center of the NAMs revolution with key industry events and research.

ImmunoBrain's novel immunotherapy for Alzheimer's avoids key safety issues of other drugs and shows positive biomarker data in a Phase 1b trial.

Annovis Bio's new trial for buntanetap uses an AI-powered Apple Watch app to track symptoms, aiming for more precise data in the race for a cure.

With a new CFO who helped steer a multi-billion dollar acquisition, Bambusa Therapeutics signals major growth plans for its innovative antibody platform.

A new biotech spins out with a novel drug class aiming to provide healthier, more durable weight loss and combat cancer-related wasting syndrome.

Ractigen's RAG-01 advances with NMPA approval, using RNA activation to fight bladder cancer by targeting a previously 'undruggable' gene.

A new drug shows unprecedented activity against all common cold viruses, a major breakthrough for millions suffering from chronic lung diseases.

Quebec’s new budget maintains support for its vital life sciences sector, but industry leaders warn new tax rules could hinder innovation for small firms.

As its new obesity drug enters a key trial, Biohaven bets on a novel approach: reducing fat while preserving precious muscle mass. Can it redefine weight loss?

Belief BioMed's single-dose treatment for hemophilia B, BBM-H901, is now approved in Macao, offering a new horizon for patients beyond frequent injections.